Ghrelink's novel neuroprotective effects in Parkinson's disease are mediated by AMP-activated protein kinase (AMPK)

  • Andrews, Zane (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date5/01/0931/12/11

Funding

  • National Health and Medical Research Council (NHMRC) (Australia): AUD385,500.00